

## CURRICULUM VITAE

### PERSONAL DATA

Name: A. Mark Fendrick, M.D.  
Address: University of Michigan Medical Center  
Division of General Medicine  
300 North Ingalls; Suite 7E06; Box 0429  
Ann Arbor, MI 48109-0429  
Telephone: (734) 647-9688  
Fax: (734) 615-2269 or (734) 936-8944  
e-mail: amfen@umich.edu  
Citizenship: United States

### EDUCATION

1974-78 Scranton Central High School, Scranton, Pennsylvania  
1978-82 University of Pennsylvania (Economics/Chemistry)  
Philadelphia, Pennsylvania, B.A.  
1982-87 Harvard Medical School, Boston, Massachusetts, M.D.

### POSTDOCTORAL TRAINING

1984-85 Charles A. Dana Foundation Scholar, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania  
1987-90 Internship/Residency - Department of Internal Medicine, University of Pennsylvania, Medical Center, Philadelphia, Pennsylvania  
1991-93 Robert Wood Johnson Foundation Clinical Scholar, University of Pennsylvania School of Medicine, Division of General Internal Medicine, Department of Medicine, University of Pennsylvania Medical Center and Philadelphia Veterans Affairs Medical Center

### ACADEMIC APPOINTMENTS

1985- Senior Fellow, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania  
1990 Research Associate, Swedish Council on Technology Assessment in Health Care, Stockholm, Sweden  
1991 Visiting Research Professor, Assistance Publique-Hospitaux de Paris, Ecole Polytechnique, Paris, France  
1992-94 Lecturer, Department of Health Care Systems, Wharton School of Business, University of Pennsylvania, Philadelphia, Pennsylvania  
1993-98 Assistant Professor, Division of General Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan  
1993-98 Assistant Professor, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan  
1996- Co-Director, Consortium for Health Outcomes Innovation Cost Effectiveness Studies (CHOICES), Department of Internal Medicine, University of Michigan School of Medicine

1998-2003	Associate Professor, Division of General Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
1998-2003	Associate Professor, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan
1998-	Core Faculty, Robert Wood Johnson Clinical Scholars Program, University of Michigan, Ann Arbor, Michigan
2002-	Director, Health Services Research Core Laboratory, University of Michigan, Ann Arbor, Michigan
2002-	Core Faculty, Society of General Internal Medicine - Hartford Foundation Collaborative Center for Research and Education in the Care of Older Adults
2003-	Professor, Division of General Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
2003-	Professor, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan

### CONSULTING POSITIONS

1993-	Merck and Co., West Point, Pennsylvania
1994-	Astra Zeneca Pharmaceuticals, Wayne, Pennsylvania
1996-2002	Merck-Medco, Inc., Montvale, New Jersey
1997-	Procter & Gamble, Cincinnati, Ohio
1997-2002	Glaxo SmithKline, Philadelphia, Pennsylvania
2001-2003	Pfizer, Inc
2002-	Eli Lilly and Company
2002-	TAP Pharmaceuticals, Lake Forest, Illinois
2002-	Aventis Pharmaceuticals

### SCIENTIFIC ACTIVITIES

#### Editorships

2002-	Co-Editor in Chief, American Journal of Managed Care
-------	--

#### Editorial Boards

1995-2002	Journal of Clinical Outcomes Management
1996-2002	Gastroenterology Therapy On-Line ( <a href="http://www.gastrotherapy.com">http://www.gastrotherapy.com</a> )
1997-2002	American Journal of Managed Care
1999-	Evidence-Based Gastroenterology
2002-	Clineguide

#### Grant Review

1996	<i>Cost-Reducing Health Care Technologies</i> , National Science Foundation and the Whitaker Foundation, Washington, D.C.
1998-1999	National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Special Emphasis Panel
2001	Medical Research Council (United Kingdom). Expert Reviewer, Physiological Medicine and Infection Board.
2002-	National Institutes of Health, Health Services Organization and Delivery Study Section, (formerly SNEM 4).

### GRANT SUPPORT

Recent

National Institutes of Health – Agency for Health Care Policy and Research. Medical Innovation and Changes in Practice Patterns. Co-Principal Investigator.

American Society of Clinical Oncology. Radiation Therapy effort DCIS: Utilities and Cost-Effectiveness. Mentor.

Aventis. The Clinical and Economic Effects of Antibiotic Therapy in Acute Exacerbation of Chronic Bronchitis. Co-Principal Investigator.

Merck & Co., Inc. Measuring Indirect Costs of Dementia Care Using a Longitudinal Study of US Elderly. Principal Investigator.

National Institutes of Aging. Computerized Calendar Methods – Health and Economic Measures. Co-Investigator.

Ortho Biotech. Out of Pocket Costs for the Elderly with Cancer. Principal Investigator.

Current

National Patient Safety Foundation. Enhancing Patient Safety by Reducing Inappropriate Urinary Catheterization. Co-Investigator. Sanjay Saint, Principal Investigator.

Department of Veteran’s Affairs, Health Services Research and Development. Economic Impact of Guidelines for Gastroesophageal Reflux Disease. Co-Investigator. John Inadomi, Principal Investigator.

Robert Wood Johnson Foundation, Clinical Scholars Program Grant. Core Faculty. Joel Howell, Principal Investigator.

University of Michigan Medical Center. Health Services Research Core Laboratory. Principal Investigator.

Agency for Health Care Research and Quality. Targeting Interventions to Reduce Errors. Co-Investigator. Tim Hofer, Principal Investigator.

National Institutes of Health. Training Grant for Cell and Molecular Dermatology. Preceptor. JT Elder, Principal Investigator

National Institutes of Health. Gastrointestinal Hormone Research Core Center. Investigator. Chung Owyang, Principal Investigator.

National Institutes of Health/NHLBI. Multidisciplinary Training Program on Lung Disease. Faculty Trainer. Galen Toews, Principal Investigator PI. National Institutes of Health

National Institutes of Health/National Institute of Child Health and Human Development, Building Interdisciplinary Research Careers in Women’s Health. Mentor.

Agency for Health Care Research and Quality, Healthcare Technology and Decision Sciences (HTDS). The Role of Technology in Health Care Cost Growth Investigator. Michael Chernew, Principal Investigator.

Pending

National Institutes of Health. Outcomes of Triaged Family Care in Advanced Cancer. Co-Investigator. Laurel Northouse, PI.

Centers for Medicare and Medicaid Services. Evaluation of the Medicare Prescription Drug Discount Card and Transitional Assistance Program. Co-Investigator. Richard Hirth, PI.

National Institutes of Health. Mammography as a “Teachable Moment” in Improving Colorectal Cancer Screening. Co-Investigator. Ruth Carlos, PI

**CERTIFICATION AND LICENSURE**

1987-93	Pennsylvania (#042468-E)
1991	American Board of Internal Medicine (#135516)
1993-	Michigan (#4301062417)

**HONORS AND AWARDS**

1978	Pennsylvania State Senatorial Scholar
1980	Alpha Epsilon Delta Honor Society
1982	Summa cum laude, University of Pennsylvania
1992, 1993	American Federation for Clinical Research Trainee Award
1996	Governors' Award, American College of Gastroenterology
1997	Best Poster Prize, 13th Annual Meeting of the International Society for Technology Assessment in Health Care, Barcelona, Spain.
2001	Best Podium Presentation, 4 <sup>th</sup> Annual European Congress, International Society for Pharmacoeconomics and Outcomes Research, Cannes, France.
2004-2006 MBA)	Society of General Internal Medicine, Research Mentorship Award (with Peter Cram, MD,

**MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES**

	Member, American College of Physicians
	Member, American Federation for Clinical Research
	International Society for Technology Assessment in Health Care, Board of Directors, 1995-1998
	Member, Physicians for a National Health Program
	Member, Society of General Internal Medicine
	Member, Society for Medical Decision Making
	Member, Central Society for Clinical Research
1997-	Member, American Gastroenterological Association
1996-	Member, American College of Gastroenterology
1996-	International Society for Pharmacoeconomics and Outcomes Research, Board of Directors, 2000-2002

**TEACHING ACTIVITIES***National*

1991-93	Faculty, The Health Care System, Wharton School of Business, University of Pennsylvania, Philadelphia, Pennsylvania
---------	---

*University of Michigan (selected since 2000)*

May 2000	Patient Risk Stratification: The Future of Clinical Care. Grand Rounds, Department of Internal Medicine
Aug 2000	Economic Evaluation of Medical Interventions and Decision Analysis. Robert Wood Johnson Clinical Scholars Program
Sept 2000	Economic Evaluation of Medical Interventions. Department of Physical Medicine and Rehabilitation Research Seminar
Nov 2000	Role of Economic Evaluation in Genetic Testing and Diagnosis. Health Management and Policy 517, School of Public Health
Dec 2000	Critical Appraisal of the Medical Literature and Application to Clinical Care, Senior Elective (Component IV), School of Medicine
Aug 2001	Collaborations with the For-profit Research Sector. Robert Wood Johnson Clinical Scholars Program
Dec 2001	Economic Evaluation and Decision Analysis, Critical Appraisal Elective, School of Medicine

Dec 2001	Broad Thinking Before Broad Coverage: A Practical Approach to the Appropriate Use of Antibiotics for Respiratory Tract Infections. Noon Conference, Department of Internal Medicine
April 2002	Cost Benefit - Cost Effectiveness Analysis. K30 Training Program in Clinical Research
Nov 2002	Physician Practice Variation: What is it, Why is it, What next? Grand Rounds (Panelist), Department of Internal Medicine
Nov 2002	Outcomes Research. K30 Training Program in Clinical Research
Dec 2002	Reducing NSAID Gastropathy with COX-2 Inhibitors: Does an Aspirin a Day Take the Benefit Away? Grand Rounds, Department of Internal Medicine
Dec 2002	The Benefit Based Co-Pay: Using Outcomes Research to Get Prescription Drugs to People Who Need Them. Robert Wood Johnson Clinical Scholars Program
April 2003	Reducing NSAID Complications in the COX-2 era: Does an Aspirin a Day Take the Benefit Away? Morning Report, Department of Internal Medicine
May 2003	Health Services Research. K30 Training Program in Clinical Research
May 2003	The Benefit Based Co-Pay: Using Outcomes Research to Get Prescription Drugs to Children Who Need Them. Division of General Pediatrics
July 2003	Reducing NSAID Complications in the COX-2 era: Does an Aspirin a Day Take the Benefit Away? Morning Report, Department of Internal Medicine
Oct 2003	Colorectal Cancer Prevention: A GI Outsider Take and Insider Look. Noon Conference, Department of Internal Medicine
Nov 2003	When Two Rights Make a Wrong: Maximizing Benefits, Minimizing Risks of Aspirin, NSAIDs and Their Combination. Morning Report, Department of Internal Medicine
Dec 2003	Economic Evaluation and Decision Analysis, Critical Appraisal of the Medical Literature and Application to Clinical Care, Senior Elective (Component IV), School of Medicine
Mar 2004	Economic Evaluation and Decision Analysis, Critical Appraisal of the Medical Literature and Application to Clinical Care, Senior Elective (Component IV), School of Medicine
Apr 2004	GI Protection and Use of NSAIDS/COX-2 Agents, 32 <sup>nd</sup> Annual Spring Update in Internal Medicine, Department of Internal Medicine

#### **EXTRAMURAL INVITED PRESENTATIONS**

##### *International (selected since 2000)*

"Economics of Wound Care: Reimbursement and the Future of New Technologies." The Wound Healing Society Educational Symposium, Toronto, Canada, June 2000.

"Cost-Effectiveness of Combined Hepatitis B and Hib Vaccines." Economic Evaluation of Hepatitis A and B Vaccination, Viral Hepatitis Prevention Board, Istanbul, Turkey, October 2000.

"Role of initial NSAID choice and patient risk factors in cost-effectiveness of treatment to prevent NSAID gastropathy". Rheumatology Rounds. McGill University, Montreal, Canada, April 2001.

"The Benefit Based Co-Pay: Using Outcome Research to Get Prescription Drugs to People who Most Need Them". Medical Grand Rounds, The Montreal General Hospital, Montreal, Quebec, January 2002.

"Rx to OTC Switches: How Changes are Handled Within the Pharmacy Benefit." Academy of Managed Care Pharmacy 2003 Educational Conference, Montreal, Canada, October 2003.

##### *National (selected since 2000)*

"GERD: Simple Heartburn or Serious Disease?" American Pharmaceutical Association, Washington, DC, March 2000.

- "Management of an Individual with Heartburn who fails OTC Histamine-2 Antagonist Therapy." American College of Osteopathic Family Physicians. Las, Vegas, Nevada, March 2000.
- "GERD in the New Millennium: Clinical, Economic and Quality of Life Issues." Division of Gastroenterology, University of Miami School of Medicine, Miami, Florida, March 2000.
- "Which Agent When for Arthritis and Pain?" National Association of Managed Care Physicians Medical Directors, Dallas, Texas, March 2000.
- "Treatment of Erectile Dysfunction: At What Cost?" Academy of Managed Care Pharmacy, Phoenix, Arizona, April 2000.
- "Which Agent When for Arthritis: Role of Outcomes Research in making NSAID Choices." Grand Rounds, UNT-Health Science Center, Fort Worth, Texas, May 2000.
- "Lifestyle Drugs: Benefit or Not." Texas Association of Health Plans, League City, Texas, May 2000.
- "Diagnosis of *Helicobacter pylori* Infections." Contemporary Topics in Clinical Microbiology and Infectious Disease, SUNY Upstate School of Medicine, Syracuse, New York, June 2000.
- "Access to New Pharmaceuticals: The Role of Outcomes Research." Internal Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, Wisconsin, June 2000.
- "Outcomes Research: Impact on New Healthcare Technology Development." World Congress on Medical Physics and Biomedical Engineering, Chicago, Illinois, July 2000.
- "NSAID Choice in the COXib Era: The Role of Outcomes Research." Northwestern University, Division of Rheumatology, Chicago, IL, July 2000.
- "Treatment of GERD: Clinical and Economical Perspectives." Grand Rounds, Winchester Hospital, Winchester, MA, September 2000.
- "Enhancing Patient Safety." Georgia Leadership Council, Atlanta, GA, November 2000.
- "Access to Treatments for Erectile Dysfunction: Clinical, Economic, & Quality of Life Considerations." The Pharmacologic Management of Male Sexual Dysfunction and Critical Issues in Female Sexual Dysfunction, Beverly Hills, California, November 2000.
- "Outcomes Analysis." Wright State University School of Medicine, Dayton, Ohio, November 2000.
- "A Practical Approach to Diagnosis and Appropriate Use of Anti-Infectives for RTI." American Society of Health System Pharmacists, Las Vegas, Nevada, December 2000.
- "Successful Strategies in the Management of Dementia." AAGP Annual Meeting, Orlando, Florida, February 2002.
- "Colorectal Cancer Prevention: A GI Outsider Take and Insider Look." The Visiting Professor Lecture Series, UCLA, Los Angeles, California, March 2002.
- "The Role of Outcomes Research in Clinical Decisions." ISPOR Clinical Practice Forum, Crystal City, Virginia, May 2002.
- "Expanding Use of Over the Counter Medications: A Primary Care Provider's Perspective." Consumer Health Products Association Scientific Affairs Committee, May 2002.
- "COX-2 inhibitors and Acid-Suppressants in Patients at Risk for NSAID-Associated Gastropathy." JPC Foundation, New York, New York, June 2002.
- "Management Update on GERD and Dyspepsia." Georgia Association of Physician Assistants. Jekyll Island, GA, July 2002.
- "Optimizing Treatment Regimens for Patients at risk for NSAID-related adverse events. Alabama Medical Directors Association, Destin, FL, July 2002.
- "NSAID-induced Ulcerations: What is the Role of Cox-II Inhibitors?" Southern Illinois University School of Medicine, Springfield, IL, September 2002.

- "The Use and Effect of OTC Omeprazole for Frequent Heartburn". American College of Gastroenterology. Seattle, WA, October 2002.
- "Optimizing Treatment for Patients at Risk for NSAID-Related Adverse Events". Division of Gastroenterology, University of Kentucky. Lexington, KY, October 2002.
- "Optimizing Treatment for Patients at Risk for NSAID-Related Adverse Events". Grand Rounds, St. Vincent Hospital, Indianapolis, IN. October 2002.
- "Expanding the Use of Over the Counter Medications in an Evolving Health Care System" Consumer Healthcare Products Association Public Affairs Committee. Washington, DC. January 2003.
- "Defining a Cost-effectiveness Acceptability Criterion: Is One Needed? How Should it be Identified?" Meeting of International Society for Pharmacoeconomics and Outcomes Research. Arlington, VA. May 2003.
- "When to consider empiric therapy for heartburn" Grand Rounds, New Britain General Hospital. New Britain, CT. February 2003.
- "Optimizing treatment of patients at risk for NSAID related adverse events" Internal Medicine Grand Rounds, Robert Wood Johnson Medical School. New Brunswick, NJ. February 2003.
- "Heartburn: Mild and Persistent" American Pharmaceutical Association. New Orleans, LA. March 2003.
- "The Benefit Based Co-Pay: Using Outcomes Research to Get Prescription Drugs to People Who Need Them" Department of Health Care Policy, Harvard Medical School. Boston, MA. June 2003.
- "When Two Rights Make a Wrong: Maximizing Benefits, Minimizing Risks of Aspirin, NSAIDs and their Combination." Division of Gastroenterology, University of North Carolina. Chapel Hill, NC. June 2003.
- "The Benefit Based Co-Pay: Using Outcomes Research to Get Prescription Drugs to People Who Need Them." Centers for Medicare and Medicaid Services. Baltimore, MD. June 2003.
- "Issues and Answers in Colorectal Cancer Screening." PRI-MED Symposium, Rosemont, IL. June 2003.
- "When Two Rights Make a Wrong: Maximizing Benefits, Minimizing Risks of Aspirin, NSAIDs and their Combination." Grand Rounds, Department of Internal Medicine, University of Pennsylvania School of Medicine. Philadelphia, PA. June 2003.
- "Translating Industry-sponsored Research into Practice: Hurdles and Questions." Translating Research into Practice, AHRQ Conference. Washington, DC. July 2003.
- "Does an Aspirin a Day Take the Benefit Away? Preventing NSAID-Related Adverse Events in the Coxib Era." Grand Rounds, Department of Internal Medicine, Oklahoma University Health Sciences Center. Oklahoma City, OK. September 2003.
- "When Two Rights Make a Wrong: Maximizing Benefits, Minimizing Risks of Aspirin, NSAIDs and their Combination." Grand Rounds, Division of Rheumatology, University of Maryland, Baltimore, MD. October 2003.
- "Socioeconomic and Pharmacoeconomic Issues in Mild-to-Moderate Pain." US Department of Health and Human Services, Office on Women's Health, Washington, DC. December 2003.
- "Economic Models of Colorectal Cancer Screening in Average-Risk Adults." Institute of Medicine, National Academy Sciences, Washington DC. January 2004.
- "Optimizing Treatment for Patients at Risk for NSAID-Related Adverse Events". Division of Gastroenterology, University of Louisville School of Medicine. Louisville, KY. January 2004.
- "When Two Rights Make a Wrong: Maximizing Benefits, Minimizing Risks of Aspirin, NSAIDs and their Combination." Grand Rounds, Methodist Hospital, Houston, Texas, February 2004.
- "When Two Rights Make a Wrong: Maximizing Benefits, Minimizing Risks of Aspirin, NSAIDs and their Combination." Grand Rounds, Department of Family Medicine, John Peter Smith Hospital, Fort Worth, Texas, February 2004.
- "Optimizing Treatment for Patients at Risk for NSAID-Related Adverse Events." Department of Internal Medicine, University of Miami School of Medicine. Miami, Florida, March 2004.

"Clinical Presentation and Diagnosis of Heartburn and GERD." American Pharmaceutical Association. Seattle, WA. March 2004.

*Local (selected since 2000)*

"Which Agent When for Arthritis and Pain? Department of Pharmacy, Detroit Medical Center, Detroit, Michigan, January 2000.

"Access to New Pharmaceuticals: Clinical, Economic and Quality of Life Considerations." Southeast Michigan Society of Health System Pharmacists. Southfield, Michigan, March 2000.

"Outcomes Research and GERD." Michigan Nurses Association, Grand Rapids, Michigan, March 2000.

"Role of Outcomes Research in Choosing Treatment Options for Osteoarthritis." Oakwood Hospital, Department of Pharmacy, Dearborn, Michigan, May 2000.

"The Role of Outcome Research in Evaluating New Pharmaceuticals: The Case of NSAID Therapy." Saginaw Cooperative Hospitals, Inc., Saginaw, Michigan, June 2000.

"Stress and Irritable Bowel Syndrome." Michigan Academy of Family Physicians – 2000 Annual Scientific Assembly, Harbor Springs, MI, July 2000.

"Therapeutic Options in Managing High Risk Patients with Osteoarthritis." Veterans Affairs Integrated Service Network II (VISN II) Pharmacists, Ann Arbor, MI, October 2000.

"Which Agent When for Arthritis and Pain?" Department of Pharmacy, Beaumont Health System, Troy, Michigan, December 2000.

"A Practical Approach to Diagnosis and Appropriate Use of Anti-Infectives for RTI's". St. Clair County – CME Consortium, Port Huron, MI, January 2002.

"Assessing the Risk of Barrett's Esophagus and Adenocarcinoma in the Patient with Chronic GERD". Internal Medicine Grand Rounds, McLaren Regional Medical Center, Flint, MI, January 2002

"Assessing the Risk of Barrett's Esophagus and Adenocarcinoma in the Patient with Chronic GERD". Internal Medicine Grand Rounds, Botsford Hospital, Farmington Hills, MI, March 2002

"GI Complications Due to Long Term Use of NSAIDs". Gastroenterology Grand Rounds, Bixby Medical Center, Adrian, MI, October 2002.

"Selection of NSAID Therapy in Osteoarthritis". Michigan Quality Improvement Consortium Medical Directors' Group Meeting. Wixom, MI. January 2003.

"Colorectal Cancer Prevention: A GI Outsider Take and Insider Look." Toledo Area GUT Club, Toledo, Ohio. December 2003.

"Socioeconomic and Pharmacoeconomic Issues in Managing Mild to Moderate Pain." Section of Physical Medicine and Rehabilitation, Department of Internal Medicine, Saint Joseph Mercy Hospital, Ann Arbor, MI. February 2004.

**VISITING PROFESSORSHIPS**

Feb. 1998	Oregon Health Sciences University
Feb. 1998	University of Connecticut Health Science Center
Oct. 1998	University of New Mexico School of Medicine
Nov. 1998	McMaster University
June 2000	Medical College of Wisconsin
March 2002	University of California at Los Angeles
February 2003	Temple University
September 2003	Oklahoma University Health Sciences Center

**COMMITTEE AND ADMINISTRATIVE SERVICES**

*International*

1997	Poster Prize Committee, 14th International Meeting of ISTAHC. Barcelona, Spain.
1998	Scientific Program Committee, 15th International Meeting of ISTAHC. Ottawa, Canada.
1998	Legislative and Governmental Affairs Committee, International Society for Pharmacoeconomics and Outcomes Research.
2002	Scientific Program Committee, 18 <sup>th</sup> International Meeting of ISTAHC. Berlin, Germany.
2003	Scientific Program Committee, 19 <sup>th</sup> International Meeting of ISTAHC, Alberta, Canada.
 <i>National</i>	
1991-93	Organizing Committee, Improving the Process of Surgical Innovation. Institute of Medicine, National Academy of Sciences, Washington, D.C.
1991-94	Executive Committee, Biliary Tract Disease Patient Outcome Research Team (PORT), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
1992	Organizing Committee, Improving Coverage and Adoption Decisions About New Medical Technologies. Institute of Medicine, National Academy of Sciences, Washington, D.C.
1992-93	Clinical Preventive Services Committee, Health Promotion Council of Southeastern Pennsylvania
1994	Abstract Review Committee, 10th Annual Meeting of the International Society for Technology Assessment in Health Care. Baltimore, Maryland
1994-	Prostate Cancer Advisory Committee, State of Michigan Department of Public Health, Center for Health Promotion, Cancer Prevention and Control Unit
1994	Gastroesophageal Reflux Disease Working Group, American College of Gastroenterology, Arlington, Virginia
1993-	FHP Prize Selection Committee. International Society for Technology Assessment in Health Care
1995-99	<i>Helicobacter pylori</i> Study Advisory Group, Kaiser Permanente Division of Research, Oakland, California
1995-96	Editorial Review Panel, <i>Prostate Disorders</i> , Time Life Medical Videos
1996	Research and Education Committee, Society for Health Services Research in Radiology
1996-2000	Fellowship Committee, Association for Pharmacoeconomics and Outcomes Research
1996-98	Task Force on Clinical Outcomes Studies, American College of Gastroenterology
1996-	Cost-effectiveness Subcommittee, National Emphysema Treatment Trial (NETT), National Institutes of Health
1997	Clinical Advisory Workgroup, Peptic Ulcer Quality Improvement Project, Health Care Financing Administration (HCFA), Department of Health & Human Services
1997	Advisor, Prudential Guidelines Committee, Prudential Health Care
1997-	Medical Advisory Board, Best Doctors Care Access Network, Best Doctor™ - Worldwide Medical Information Services
1997-	Medical Advisory Board, Health Communications, Inc., Darien, Connecticut
1998-	Chair, Issues Panels, International Society for Pharmacoeconomics and Outcomes Research 5 <sup>th</sup> Annual International Meeting, Arlington, Virginia
2002-	Expert Reviewer, Management of Chronic Hepatitis C. Evidence Report/Technology Assessment #60. AHRQ Publication 02-E030. Agency for Healthcare Research And Quality.
2003-	Medical Advisory Board, Pri-Med Institute
2003-	Cost-effectiveness Subcommittee, Chronic Renal Insufficiency Cohort Study (CRIC), National Institutes of Health
2004-	Centers for Medicare and Medicaid Services, Medicare Coverage Advisory Committee (MCAC)

- 2004 Panelist, National Institutes of Health Consensus Development Conference on Celiac Disease
- University of Michigan*
- 1994 Course Planning Committee, Advances in Internal Medicine, 22nd Annual Spring Update, Department of Internal Medicine
- 1995- Grant Review Committee, Office of the Vice President for Research
- 1995- Peptic Ulcer Disease Guidelines Working Group
- 1996- Grant Review Committee, University of Michigan Small Grant Program
- 1998-2002 Co-Chair, Managed Care Task Force, Health Services Research Initiative, University of Michigan School of Medicine
- 1999- Advisor, Advanced Rehabilitation Research Training Program
- 1998-2002 Abstract Review, Department of Internal Medicine Research Symposium
- 2002- Chair, Collaborative Health Services Research Initiative for Practice Improvements, University of Michigan Health System
- 2002- Awards Committee, Department of Internal Medicine
- 2002- Executive Committee, Center for the Advancement of Clinical Research
- 2003- Advisory Committee, K30 Clinical Research Training Program, University of Michigan Medical School
- 2003 Grant Reviewer, Life Sciences, Values and Society Program

#### **COMMUNITY SERVICE**

- 1991-93 Volunteer Physician, Community Health Group, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
- 1993- Volunteer Physician, Lynn Hadley Clinic, Ann Arbor, Michigan

#### **BIBLIOGRAPHY**

##### *Publications in Scientific Journals*

##### *Peer-Reviewed Publications*

1. Bloom BS, Fendrick AM. Waiting for Care: Queuing and Resource Allocation. *Medical Care.* 1987;25:131-9.
2. Bloom BS, Fendrick AM, Ramsey SD. Changes in Peptic Ulcer Disease and Gastritis/Duodenitis in Great Britain 1970-1985. *Journal of Clinical Gastroenterology.* 1990;12:100-8.
3. Lee TH, Cook EF, Fendrick AM, et al. Impact of Initial Triage Decision on Nursing Intensity in Patients with Chest Pain. *Medical Care.* 1990;28:737-45.
4. Fendrick AM, de Pouvourville G, Bitker C, Pelletier G. Treatment of Symptomatic Cholelithiasis in France: A Decision Analysis comparing Cholecystectomy and Biliary Lithotripsy. *International Journal of Technology Assessment in Health Care.* 1992;8:166-84.
5. Hillman AL, Bloom BS, Fendrick AM, Schwartz JS. Cost and Quality Effects of Alternative Treatments for Persistent Gastroesophageal Reflux Disease. *Archives of Internal Medicine.* 1992;152:1467-72.
6. Fendrick AM, Javitt JC, Chiang YP. Cost-Effectiveness of the Screening and Treatment of Diabetic Retinopathy. *International Journal of Technology Assessment in Health Care.* 1992;4:694-707.
7. Gelijns AC, Fendrick AM. The Dynamics of Innovation on Minimally Invasive Therapy. *Health Policy.* 1993;23:153-66.
8. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A Reappraisal of Hepatitis B Vaccination Using Cost-effectiveness Analysis. *Annals of Internal Medicine.* 1993;118:298-306.
9. Fendrick AM, Gleeson SP, Cabana MD, Schwartz JS. Asymptomatic Gallstones Revisited: Is There a Role for Laparoscopic Cholecystectomy? *Archives of Family Medicine.* 1993;2:959-968.

10. Fendrick AM, Ridker PM, Bloom BS. Improved Health Benefits of Increased Use of Thrombolytic Therapy. *Archives of Internal Medicine*. 1994;154:1605-9.
11. Fendrick AM, Escarce JJ, McClane C, Shea JA, Schwartz JS. Hospital Adoption of Laparoscopic Cholecystectomy. *Medical Care*. 1994;32:1058-63.
12. Trobe JD, Fendrick AM. The Effectiveness Initiative Part 1: Medical Practice Guidelines. *Archives of Ophthalmology*. 1995;113:715-717.
13. Fendrick AM, Goodman CS, Trobe JD. The Effectiveness Initiative Part 2: The Spectrum of Effectiveness Research. *Archives of Ophthalmology*. 1995;113:862-865.
14. Fendrick AM. Clinical and Economic Assessment of New Surgical Technologies. *Journal of the National Cancer Institute*. 1995;19:57-60.
15. Feld S, Pritzker JG, Lockett AR, Fendrick AM, et al. A Case-Based Review of the AACE Clinical Practice Guidelines for the Management of Thyroid Disease. *Journal of Clinical Outcomes Management*. 1995;2:29-38.
16. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative Management Strategies for Patients with Suspected Peptic Ulcer Disease. *Annals of Internal Medicine*. 1995;123:260-268.
17. Fennerty MB, Castell DO, Fendrick AM, Halpern M, et al. The Diagnosis and Treatment of GERD in a Managed Care Environment. Suggested Disease Management Guidelines. *Archives of Internal Medicine*. 1996;156:477-484.
18. Bloom BS, Fendrick AM, McClane C. Predicting Effects of Minimally Invasive Therapy. *Health Policy*. 1996;35:179-187.
19. Bloom BS, Fendrick AM. The Tension Between Cost Containment and the Underutilization of Effective Health Services. *International Journal of Technology Assessment in Health Care*. 1996;12:1-8.
20. Fendrick AM, Chernew ME, Hirth RA, Menon D. Understanding the Behavioral Response to Medical Innovation. *American Journal of Managed Care*. 1996;2(7):793-799.
21. Scheiman JM, Conaway DC, Fendrick AM. Optimizing Outcomes for Patients at Risk for NSAID-Induced Ulcer Disease. *Journal of Clinical Outcomes Management*. 1996;3(5):23-36.
22. Bloom BS, Fendrick AM. Timing and Timeliness in Medical Care Evaluation. *Pharmacoeconomics*. 1996;9:183-187.
23. Fendrick AM, Hirth RA, Chernew ME. Differences Between Generalist and Specialist Physicians Regarding *Helicobacter Pylori* and Peptic Ulcer Disease. *American Journal of Gastroenterology*. 1996;91:1544-1548.
24. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and Economic Effects of Mupirocin on Preventing *Staphylococcus Aureus* in Hemodialysis Patients: A Decision Analysis. *American Journal of Kidney Disease*. 1996;27(5):687-694.
25. Hirth RA, Fendrick AM, Chernew ME. Specialist and Generalist Physicians' Adoption of Antibiotic Therapy to Eradicate *Helicobacter Pylori* Infection. *Medical Care*. 1996;34(12):1199-1204.
26. Olson AD, Fendrick AM, Deutsch D, Chernew ME, Hirth RA, Patel C, Bloom B. Evaluation of Initial Non-Invasive Therapy in Pediatric Patients Presenting with Suspected Ulcer Disease. *Gastrointestinal Endoscopy*. 1996;44(5):554-561.
27. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Immediate Endoscopy or Initial *Helicobacter Pylori* Serological Testing for Suspected Ulcer Disease: Estimating Cost-effectiveness Using Decision Analysis. *The Yale Journal of Biology and Medicine*. 1996;69(2):187-195.
28. McDonnell WM, Lok AS, Fendrick AM. Diagnostic and Treatment Strategies in Hepatitis C Virus Infection. *Journal of Clinical Outcomes Management*. 1996;3(6):15-24.
29. Chernew ME, Fendrick AM, and RA Hirth. Managed Care and Medical Technology: Implications for Health Care Cost Growth. *Health Affairs*. 1997;16:196-206.
30. Krumholz HM, Fendrick AM, Williams C, Hynes WM. Differences in Physician Compensation for Cardiovascular Services by Age, Sex, and Race. *The American Journal of Managed Care*. April 1997;3(4):557-563.
31. Fendrick AM. Outcomes Research in *Helicobacter Pylori* Infection. *Alimentary Pharmacology and Therapeutics*. April 1997;11(1):95-101.

32. Fendrick AM, McCort JT, Chernew ME, Hirth RA, Patel C, Bloom BS. Immediate Eradication of *Helicobacter Pylori* In Patients With Previously Documented Peptic Ulcer Disease: Clinical And Economic Effects. *American Journal of Gastroenterology*. 1997;92:2017-2024.
33. De Pouvourville G, Ribet-Reinhart N, Fendrick AM, Houry S, Testas P, Huguier M. Prospective Comparison of Costs and Morbidity of Laparoscopic versus Open Cholecystectomy. *Hepato-Gastroenterology*. 1997;44:35-39.
34. Scanlon DP, Chernew M, Sheffler S, Fendrick AM. Health Plan Report Cards: Exploring Differences in Plan Ratings. *Joint Commission Journal on Quality Improvement*. 1998;24(1):5-20.
35. Fendrick, AM, Chey, W. Approach to the Patient with *Helicobacter Pylori* - Associated Epigastric Pain. *Journal of Clinical Outcomes Management*. 1998;5(1)41-48. Reprinted in *Hospital Physician*. 1998;34(2):36-44.
36. Laine L, Fendrick AM. *Helicobacter pylori* and Peptic Ulcer Disease. Bridging the Gap between Knowledge and Treatment. *Postgraduate Medicine*. 1998;103(3):231-243.
37. Moss SF, Fendrick AM, Cave DR, Modlin IM. *Helicobacter Pylori* -- More Light, Less Heat. *American Journal of Gastroenterology*. 1998;93(3):306-310.
38. Dwamena BA, Kloos RT, Fendrick AM, Gross MD, Francis IR, Korobkin MT, Shapiro B. Diagnostic Evaluation of the Adrenal Incidentaloma: Decision and Cost-Effectiveness Analysis. *Journal of Nuclear Medicine*. 1998;39:707-712.
39. Chernew ME, Hirth RA, Sonnad SS, Ermann R, Fendrick AM. Managed Care, Medical Technology, and Health Care Cost Growth: A Review of the Evidence. *Medical Care Research and Review*. 1998;55:259-288.
40. Moyer CA, Fendrick, AM. Measuring Health Related Quality of Life in Patients with Upper Gastrointestinal Disease. *Digestive Diseases*. 1998;16:315-324.
41. Fendrick AM. Assessing the Cost Effectiveness of Analgesic Therapy. *Managing Chronic Pain*. *Postgraduate Medicine A Special Report*. 1998;S50-55.
42. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and Economic Effects on Population-Based *Helicobacter Pylori* Screening to Prevent Gastric Cancer. *Archives of Internal Medicine*. 1999;159:142-148.
43. Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and Economic Impact of a Combination *Haemophilus Influenzae* and Hepatitis B Virus Vaccine. *Archives of Pediatrics and Adolescent Medicine*. 1999;153:126-136.
44. Bloom BS, Tibi-Levy Y, Harari A, Fendrick, AM. Direct Medical Care Costs of Unstable Angina Pectoris in a Defined Population. *Journal of Managed Care Pharmacy*. 1999;5(1):39-44.
45. Fendrick AM, Blitz SG. Gastroesophageal reflux: Therapy Consideration After Failure Of Low-Dose, Nonprescription H<sub>2</sub>RAs. *Formulary*. 1999;34(3):234-246.
46. Graham DY, Rakel RE, Fendrick AM, Go MF, Marshall BJ, Peura DP, Scherger JS. Scope and Consequences of Peptic Ulcer Disease: How Important is Asymptomatic *Helicobacter Pylori* Infection? *Postgraduate Medicine*. 1999;105(3):100-110.
47. Graham DY, Rakel RE, Fendrick AM, Go MF, Marshall BJ, Peura DP, Scherger JS. Recognizing Peptic Ulcer Disease: Keys to Clinical and Laboratory Diagnosis. *Postgraduate Medicine*. 1999;105(3):113-133.
48. Graham DY, Rakel RE, Fendrick AM, Go MF, Marshall BJ, Peura DP, Scherger JS. Practical Advice on Eradicating *Helicobacter Pylori* Infection: Treating Peptic Ulcer Disease Cost-Effectively. *Postgraduate Medicine*. 1999;105(3):137-148.
49. Fendrick AM, Blitz SG, Reilly JP. Management Strategies for Patients with Symptomatic Gastroesophageal Reflux Disease in the OTC H<sub>2</sub>-Antagonist Era. *Journal of Clinical Outcomes Management*. 1999;6(4):55-64.
50. Hirth RA, Bloom BS, Chernew ME, Fendrick, AM. Willingness to Pay for Diagnostic Certainty: A Comparison Among Patients, Physicians, and Managers. *Journal of General Internal Medicine*. 1999;14:193-195.
51. Dent J, Brun J, Fendrick AM, et al. An Evidence-Based Appraisal of Reflux Disease Management - The Genval Workshop Report. *Gut*. 1999;44(2):S0-S15.
52. Fendrick AM, Chey WD, Magaret N, Palaniappan J, Fennerty MB. Symptom Status and the Desire for *Helicobacter Pylori* Confirmatory Testing After Eradication Therapy in Patients with Peptic Ulcer Disease. *American Journal of Medicine*. 1999;107:133-136.

53. Trobe JD, Sieving PC, Guire KE, Fendrick AM. The Impact of the Optic Neuritis Treatment Trial on the Practices of Ophthalmologists and Neurologists. *Ophthalmology*. 1999;106(11):2047-2053.
54. Moyer CA, Stern DT, Katz SJ, Fendrick AM. "We Got Mail". Electronic Communication Between Physicians and Patients: Implications for Managed Care. *American Journal of Managed Care*. 1999;5(12):1513-1522.
55. Cram P, Blitz SG, Monto A, Fendrick AM. Diagnostic Testing for Influenza: Review of Current Status and Implications of Newer Treatment Options. *American Journal of Managed Care*. 1999;5(12): 1555-1561.
56. Teitelbaum F, Roe CM, Fendrick AM. Pharmacy Management Trends: A Guide for New Physicians. *Seminars in Medical Practice*. 2000;3(1):22-31.
57. Blitz SG, Fendrick AM, Chenoweth C. Developments in the Care of Influenza: Priorities and Perspectives. *Journal of Clinical Outcomes Management*. 2000;7(2):63-72.
58. Rich M, Scheiman JM, Tierney W, Fendrick AM. Is Upper Gastrointestinal Radiography a Cost-Effective Alternative to a *Helicobacter Pylori* "Test and Treat" Strategy for Patients with Suspected Peptic Ulcer Disease? *American Journal of Gastroenterology*. 2000; 95(3):651-8.
59. Monto AS, Fendrick AM. Developments in Influenza Prevention and Treatment: A Managed Care Perspective. *Disease Management and Health Outcomes*. 2000; 7(5):1-10.
60. Hirth RA, Bloom BS, Chernew ME, Fendrick AM. Patient, Physician, and Payer Perceptions and Misperceptions of Willingness to Pay for Diagnostic Certainty. *International Journal of Technology Assessment in Health Care*. 2000; 16(1):35-49.
61. Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Ruffalo, SM, Laine L. *Helicobacter pylori*-Related Disease: Guidelines for Testing and Treatment. *Archives of Internal Medicine*. 2000; 160:1285-1291.
62. Tierney WM, Fendrick AM, Hirth RA, and Scheiman JM. The Clinical and Economic Impact of Alternative Staging Strategies for Adenocarcinoma of the Pancreas. *American Journal of Gastroenterology*, 2000; 95:1708-1713.
63. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to Pay for a QALY: In Search of a Standard. *Medical Decision-Making*, 2000; 20:332-342.
64. Stern MA, Fendrick AM, McDonnell WM, Gunaratnam N, Moseley R, Chey WD. A Randomized, Controlled Trial to Assess a Novel Colorectal Cancer Screening Strategy: The Conversion Strategy. *American Journal of Gastroenterology*, 2000; 95(8):2074-2079.
65. Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The Potential Clinical and Economic Benefits of Silver Alloy Urinary Catheters in Preventing Urinary Tract Infection. *Archives of Internal Medicine*, 2000;160(17):2670-2675.
66. Koff RS, Fendrick AM. Pharmacoeconomics of Hepatitis C. *Pharmacy and Therapeutics*, 2000; 25(9):468-475.
67. Chenoweth CE, Saint S, Martinez F, Lynch JP, Fendrick AM. The Evolution of Antimicrobial Resistance in *Streptococcus Pneumoniae*: Implications for the Treatment of Community-Acquired Pneumonia. *Mayo Clinic Proceedings*, 2000; 75(11):1161-1168.
68. Chernew MC, Cowen ME, Kirking DM, Smith DG, Valenstein P, Kostoff L, Fendrick AM. Pharmaceutical Cost Growth Under Capitation: A Case Study. *Health Affairs*, 2000;19(6):266-276.
69. Nallamotheu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS. Potential Clinical and Economic Effects of Homocyst(e)ine Lowering. *Archives of Internal Medicine*, 2000;160:3406-3412.
70. Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M. The Costs of Cancer to a Major Employer in the United States: A Case-Control Analysis. *American Journal of Managed Care*, 2000, 6(11):1243-1251.
71. Bloom BS, de Pouvourville N, Libert S, Fendrick AM. Surgeon Predictions on Growth of Minimal Invasive Therapy: The Difficulty of Estimating Technologic Diffusion. *Health Policy*, 2000;54:201-207.
72. Fendrick AM. The Role of Economic Evaluation in the Diagnosis and Treatment of *Helicobacter pylori* Infection. *Gastroenterology Clinics of North America* 2000; 29:837-851.
73. Oral H, Knight BP, Sticherling C, Kim MH, Pelosi F, Michaud GF, Fendrick AM, Strickberger SA, Morady F. Cost Analysis of Transthoracic Cardioversion of Atrial Fibrillation With and Without Ibutilide Pretreatment. *Journal of Cardiovascular Pharmacology & Therapeutics* 2000;5(4):259-266.

74. Scheiman JM, Bandekar RR, Chernew ME, Fendrick AM. *H Pylori* Screening for Individuals Requiring Chronic NSAID Therapy: A Decision Analysis. *Alimentary Pharmacology and Therapeutics* 2001;15:63-71.
75. Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, Fendrick AM, Jones R, Dent J. The Development and Initial Validation of a Brief Diagnostic Questionnaire for Gastroesophageal Reflux Disease. *American Journal of Gastroenterology* 2001; 96(1):52-57.
76. Flaherty K, Saint S, Fendrick AM, Martinez FJ. The Spectrum of Patients with Acute Bronchitis: Using Baseline Factors to Guide Empiric Therapy. *Post Graduate Medicine* 2001;109(2):39-47.
77. Groeneveld PW, Lieu TA, Fendrick AM, Hurley LB, Ackerson LM, Levin TR, Allison JE. Quality of Life Measurement Clarifies the Cost-Effectiveness of *Helicobacter Pylori* Eradication in Peptic Ulcer Disease and Uninvestigated Dyspepsia. *American Journal of Gastroenterology* 2001;96(2):338-47.
78. Saint S, Flaherty KR, Abrahamse P, Martinez FJ, Fendrick AM. Acute Exacerbation of Chronic Bronchitis: Disease-Specific Attributes that Influence the Cost-Effectiveness of Therapy. *Clinical Therapeutics* 2001;23(3)1-14.
79. Cram P, Blitz SG, Monto A, Fendrick AM. Influenza: Cost of Illness and Considerations in the Economic Evaluation of New and Emerging Therapies. *Pharmacoeconomics* 2001; 19(3):223-230.
80. Nallamothu BK, Saint S, Bielak LF, Rubenfire M, Peyser P, Sonnad S, Fendrick AM. Electron-Beam Computed Tomography in the Diagnosis of Coronary Artery Disease: A Meta-Analysis of the Literature. *Archives of Internal Medicine* 2001;161:833-838.
81. Shaw MJ, Fendrick AM, Kane RL, Adis SA, Talley NJ. Self-Report of Efficacy and Presentation Rate to Physicians in Users of Over-The-Counter Histamine 2-Antagonists. *American Journal of Gastroenterology* 2001;96(3):673-677.
82. Hayman JA, Langa KM, Kabeto MU, Katz SJ, DeMonner SM, Chernew ME, Slavin MB, Fendrick AM. Estimating the Cost of Informal Caregiving for Elderly Patients with Cancer. *Journal of Clinical Oncology* 2001;19:3219-3225.
83. Chernew M, Smith DG, Kirking DM, Fendrick AM. Decomposing Pharmaceutical Cost Growth in Different Types of Health Plans. *American Journal of Managed Care*. 2001;7:667-73.
84. Ladabaum U, Fendrick AM, Scheiman JM. Outcomes of initial *H Pylori* Testing in US Primary Care Patients with Uninvestigated Dyspepsia. *American Journal of Gastroenterology*. 2001;96(7):2051-2057.
85. Fendrick AM, Baldwin JL. Allergen-Induced Inflammation and the Role of IgE. *American Journal of Therapeutics* 2001;8:291-297.
86. Fendrick AM. Management of Patients with Symptomatic Gastroesophageal Reflux Disease: Primary Care Perspective. *American Journal of Gastroenterology* 2001;96(8)Suppl.29-33.
87. Nallamothu BK, Saint S, Saha S, Fendrick AM, Kelley K, Ramsey SD. Coronary Artery Bypass Grafting in Native Americans: Higher Risk of Death Compared to Other Ethnic Groups? *Journal of General Internal Medicine* 2001;16(8);554-558.
88. Fendrick AM, Smith DG, Chernew ME, Shaw SN. A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost. *American Journal of Managed Care* 2001;7:861-867.
89. Carlos R, Bree R, Abrahamse P, Fendrick AM. Cost-Effectiveness of Saline-Assisted Hysterosonography and Office Hysteroscopy in Evaluating Post-Menopausal Bleeding: A Decision Analysis. *Academic Radiology* 2001;8:879-87.
90. Chey W, Fendrick AM. Non-Invasive *H. Pylori* Testing for the "Test and Treat" Strategy: A Decision Analysis to Assess the Impact of Past Infection on Test Choice. *Archives of Internal Medicine* 2001;161:2129-32.
91. Saint S, Chenoweth C, Fendrick AM. The Role of Economic Evaluation in Infection Control. *American Journal of Infection Control* 2001;29(5):338-44.
92. Ladabaum U, Chopra CL, Huang G, Chernew ME, Scheiman JM, Fendrick AM. Aspirin as an Adjunct to Screening for Prevention of Sporadic Colorectal Cancer: A Cost-Effectiveness Analysis. *Annals of Internal Medicine* 2001;135:769-781.
93. Axelrod, DA, Fendrick AM, Wennberg DE, Birkmeyer JD, Siewers AE. Cardiologists Performing Peripheral Angioplasties: Impact on Utilization. *Effective Clinical Practice* 2001;4(5):191-98.
94. Langa K, Kabeto M, Chernew M, Ofstedal MB, Herzog AR, Willis RJ, Wallace RB, Mucha LM, Straus WL, Fendrick AM. National Estimates of the Quantity and Cost of Informal Caregiving for the Elderly with Dementia. *Journal of General Internal Medicine* 2001;16:770-8.

95. Olson AD, Fendrick AM, Deutsch, DE. Endoscopic Outcomes Analysis. *Gastrointestinal Endoscopy Clinics of North America* 2001; 11(4):557-68.
96. Cremieux P, Slavin MB, Fendrick AM, Hiriak T, Kosicki G. The Costs of Cancer: Cancer-Related Conditions Can Add Dramatically to Overall Costs of Care. *Journal of Managed Care Medicine* 2002; 6(1):12-19.
97. Barnett A, Cremieux PY, Fendrick AM, George M, Slavin MB. Anemia-Related Costs for Cancer Patients. *Journal of Managed Care Medicine* 2002; 6(1):20-28.
98. Fendrick AM, Garabedian-Ruffalo SM. A Clinicians' Guide to the Selection of NSAID Therapy. *Pharmacy and Therapeutics*. 2002;27:579-81.
99. Monto AS, Fendrick AM, Sarnes MW. Respiratory Illness Caused by Picornavirus Infection: A Review of Clinical Outcomes. *Clinical Therapeutics* 2001;23(10):1615-1627.
100. Fendrick AM, Saint S, Brook I, Jacobs MR, Pelton S, Sethi S. Diagnosis and Treatment of Upper Respiratory Tract Infections in the Primary Care Setting. *Clinical Therapeutics* 2001;23(10):1683-1706.
101. Ellis CN, Reiter KL, Bandekar RR, Fendrick AM. Cost-Effectiveness Comparison of Therapy for Psoriasis with a Methotrexate-Based Regimen vs. a Rotation Regimen of Cyclosporine for Microemulsion (Neoral) and Methotrexate. *Journal of American Academic Dermatology* 2002; 46:242-50.
102. Ellis CN, Reiter KL, Wheeler JR, Fendrick AM. Economic Analysis in Dermatology. *Journal of American Academic Dermatology* 2002; 46:271-83.
103. Beutels P, Edmunds WJ, Fernando A, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Pecjevis M, Van Doorslaier EKA, Van Hout BA. Economic Evaluation of Vaccination Programmes: A Consensus Statement Focusing on Viral Hepatitis. *Pharmacoeconomics* 2002; 20(1):1-7.
104. Shureiqi I, Cantor SB, Lippman SM, Brenner DE, Chernew ME, Fendrick AM. Clinical and Economic Impact of Multiple Gated Acquisition (MUGA) Scan Monitoring During Anthracycline Therapy. *British Journal of Cancer* 2002; 86:226-232.
105. Blitz SG, Cram P, Chernew ME, Monto AS, Fendrick AM. Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes. *American Journal of Managed Care* 2002;8(3): 11-17.
106. Ollendorf DA, Fendrick AM, Kinsey K, Williams GR, Oster G. Is Sepsis Accurately Coded on Hospital Bills. *Value in Health* 2002; 5:279-81.
107. Fendrick AM, Bandekar RR, Chernew ME, Scheiman JM. Role of Initial NSAID Choice and Patient Risk Factors in the Prevention of NSAID Gastropathy: A Decision Analysis. *Arthritis Care and Research* 2002; 47(1):36-43.
108. Langa K, Vijan S, Hayward R, Chernew M, Blaum C, Kabeto M, Weir D, Katz S, Willis R, Fendrick AM. Informal Caregiving for Diabetes and Diabetic Complications Among Elderly Americans. *Journal of Gerontology* 2002;57B(3):S177-S186.
109. Chernew ME, Gowrisankaran G, Fendrick AM, Payer Type and the Returns to Bypass Surgery: Evidence From Hospital Entry Behavior. *Journal of Health Economics* 2002;21(3) :451-474.
110. Hickenbottom SL, Fendrick AM, Kutcher J, Kabeto M, Katz SJ, Langa KM. A National Study of the Quantity and Cost of Informal Caregiving For the Elderly With Stroke. *Neurology* 2002; 58: 1754-1759.
111. Fendrick AM. Developing an Economic Rationale for the Use of Selective COX-2 Inhibitors for Patients at Risk for NSAID Gastropathy. *Cleveland Clinic Journal of Medicine* 2002; 69:SI59-SI64.
112. Nallamothu BK, Fendrick AM, Omenn GS. Homocyst(e)ine and Coronary Heart Disease: Pharmacoeconomic Support For Interventions to Lower Hyperhomocyst(e)inaemia. *Pharmacoeconomics* 2002;20(7): 429-442.
113. Ladabaum U, Chey WD, Scheiman JM, Fendrick AM. Reappraisal of Non-Invasive Strategies in Uninvestigated Dyspepsia: A Cost-Minimization Analysis. *Alimentary Pharmacology and Therapeutics*. 2002; 16: 1491-1502.
114. Nallamothu BK, Saint S, Eagle KA, Langa K, Fendrick AM, Hogikyan RB, Kelley K, Ramsey S. Coronary Artery Bypass Grafting on Octogenarians: Clinical and Economic Outcomes at Community-Based Healthcare Facilities. *American Journal of Managed Care*. 2002;8:749-755.
115. Fendrick AM. Cost-Effective Use of NSAIDs: Issues Pertinent to Coxib Use in Managed Care. *The American Journal of Managed Care*. 2002;8:S529-S541.

116. Langa KM, Fendrick AM, Flaherty K, Ferndando M, Kabeto MU, Saint S. Informal Caregiving for Chronic Lung Disease Among Older Americans. *Chest*. 2002;122(6):2197.
117. Ladabaum U, Fendrick AM, Glidden D, Scheiman JM. Helicobacter Pylori Test-and-Treat Intervention Compared to Usual Care in Primary Care Patients With Suspected Peptic Ulcer Disease in the United States. *American Journal of Gastroenterology*. 2002;97(12):3007-3014.
118. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and Surveillance for Barrett's Esophagus in High-Risk Groups: A Cost-Utility Analysis. *Annals of Internal Medicine*. 2003;138(3):176-186.
119. Fendrick AM, Monto AS, Sarnes M, Nightengale B. The Economic Burden of Non-Influenza-Related Viral Respiratory Infection in The United States. *Archives of Internal Medicine*. 2003;163:487-494.
120. Carlos RC, Kim HM, Hussain HK, Nghiem HV, Francis IR, Fendrick AM. Developing a Prediction Rule to Assess Hepatic Malignancy in Patients With Cirrhosis. *Amer J Radiology*. 2003;180:893-900.
121. Kocs D, Fendrick AM. Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience. *American Journal of Managed Care*. 2003;9(5):393-400.
122. Ladabaum U, Scheiman JM, Fendrick AM. Potential Effect of Cyclooxygenase-2 Specific Inhibitors on the Prevention of Colorectal Cancer: A Cost-Effectiveness Analysis. *Am Journal of Medicine*. 2003;114:546-554.
123. Fendrick AM. Viral Respiratory Infections Due to Rhinoviruses: Current Knowledge, New Developments. *Am J Ther*. 2003;10(3):193-202.
124. Axelrod DA, Fendrick AM, Carlos RC, Lederman RJ, Froehlich JB, Weder AB, Abrahamse PH, Stanley JC. Percutaneous Stenting of Incidental Unilateral Renal Artery Stenosis: Decision Analysis of Costs and Benefits. *J Endovasc Ther*. 2003;10:546-556.
125. Carlos RC, Scheiman JM, Hussain HK, Song JH, Francis IR, Fendrick AM. Making Cost-Effectiveness Analyses Clinically Relevant: The Effect Of Provider Expertise and Biliary Disease Prevalence on the Economic Comparison of Alternative Diagnostic Strategies. *Acad Radiol* 2003;10:620-630.
126. Drummond M, Brown R, Barbieri M, Fendrick AM. Use of Pharmacoeconomics Information-Report of the ISPOR Task Force on use of Pharmacoeconomic/Health Economic Information in Health Care Decision-Making. *Value Health*. 2003;6(4):407-416.
127. Cram P, Vijan S, Wolbrink A, Fendrick AM. The Impact of Including Passive Benefits in Cost-Effectiveness Analysis: The Case of Automated External Defibrillators On Commercial Aircraft. *Value in Health*. 2003;6(4):466-473.
128. Cram P, Fendrick AM, Inadomi J, Cowen ME, Carpenter D, Vijan S. The Impact of a celebrity promotional campaign on the use of colon cancer screening: The Katie Couric Effect. *Arch Intern Med*. 2003;163:1601-5.
129. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is The Price of Life and Why Doesn't It Increase at the Rate of Inflation? *Arch Intern Med*. 2003;63(14):1637-41.
130. Williams LK, Pladevall M, Fendrick AM, Elston-Lafata J, McMahon L. Differences In The Reporting Of Care-Related Patient Injuries To Existing Reporting Systems. *The Joint Commission Journal on Quality and Safety*, 2003;29(9):460-467.
131. Cram P, Vijan S, Fendrick AM. Cost-effectiveness of Automated External Defibrillator Deployment in Selected Public Locations. *J Gen Intern Med*. 2003;18:1-10.
132. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-Down From Multiple- To Single-Dose Proton Pump Inhibitors: A Prospective Study Of Patients With Heartburn Or Acid Regurgitation Completely Relieved With PPIs. *American Journal of Gastroenterology*, 2003;98(9):1940-1944.
133. Carlos RC, Axelrod DA, Ellis J, Abrahamse PH, Fendrick AM. Incorporating Patient-Centered Outcomes in Cost-Effectiveness Analysis Imaging Strategies in Renovascular Hypertension. *American Journal of Radiology*, 2003;181:1653-1661.
134. Carpenter D, Chernew M, Smith DG, Fendrick AM. Approval Time For New Drugs: Does The Source of Funding For FDA Staff Matter? *Health Affairs*, 2003;17 December  
[www.content.healthaffairs.org/cgi/content/abstract/hlthaff.w3.618](http://www.content.healthaffairs.org/cgi/content/abstract/hlthaff.w3.618)
135. Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood G, Grender J, Peura D. Self-Selection and Use Patterns of Over-the-Counter Omeprazole for Frequent Heartburn. *Clinical Gastroenterology and Hepatology*, 2004;2:117-21

136. Langa KM, Fendrick AM, Chernew ME, Kabeto MU, Paisley KL, Hayman, JA. Out-of-pocket health care expenditures Among older Americans with cancer. *Value in Health*, 2004;7(2):186-94.
137. Langa KM, Larson EB, Wallace RB, Fendrick AM, Foster NL, Kabeto MU, Weir DR, Willis RJ, Herzog AR. Out-of-Pocket Health Care Expenditures Among Older Americans with Dementia. *Alzheimer's Disease and Dementia*, 2004;7(2):186-194.
138. Langa KM, Valenstein MA, Fendrick AM, Kabeto MU, Vijan S. Extent and Cost of Informal Caregiving for Older Americans With Symptoms of Depression. *Am J Psychiatry* 2004;161:857-863.

*Non-Peer Reviewed Publications:*

1. Fendrick, AM. The 1700-Year-Old Mummy and Its *H. pylori* Antigens. *Practical Gastroenterology*. November, 1998, 35-40.
2. Fendrick, AM. Who Should be Treated for *H. pylori* Infection? *Hippocrates*. 2000; 14(4):29-32.
3. Fendrick AM. Access to Innovative Treatment of Erectile Dysfunction: Clinical, Economic and Quality of Life Considerations. *American Journal of Managed Care*, 2000; 6(12):S632-S638.
4. Fendrick AM, Berardi RR. Therapeutic Options for GERD: What's the Correct Approach? *Journal of the American Pharmaceutical Association*, 2000; 40(5):S52-S53.
5. Shehab TJ, Fendrick AM. Educational Opportunities Persist for Primary Care Physicians to Improve Quality of Care for Individuals with Hepatitis C Virus Infection. *Advances in Hepatitis C*, 2000; 1(4):11-12.
6. Saint S, Fendrick AM. Economic Evaluation: A Brief Overview. *Clinical Researcher*, 2001; 2:36-39.
7. Fendrick AM, Scheiman JM. *Helicobacter pylori* and NSAID Gastropathy: An ambiguous association. *Current Rheumatology Reports*, 2001;3(2):107-111.
8. Scheiman JM, Fendrick AM. *Helicobacter pylori* eradication for individuals on chronic NSAID therapy: should we kill the bug if you need the drug? *Practical Gastroenterology*, 2001;25(5):12-24.
9. McKinnon P, Fendrick AM, Zinner SH. Challenges in the diagnosis and management of respiratory tract infections. *U.S. Pharmacist*, July 2001, 26(7):73-82.
10. Fendrick AM, Langa KM. The Far-Reaching Effects of Alzheimer's Disease. *Elder Care*. 2002;2(4):1-4.
11. Fendrick AM, Garabedian-Ruffalo SM. Management Strategies for Individuals Who Take NSAIDs and Require Aspirin to Reduce Cardiovascular Risk. *Scope*. 2003;5:10-14

*Articles Accepted for Publication*

1. Kent DM, Fendrick AM, Langa KM. New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical Interventions. *Medical Decision Making*.
2. Banaszak-Holl J, Fendrick AM, Foster NL, Herzog AR, Kabeto MU, Kent DM, Straus WL, Langa KM. Predicting Nursing Home Admission: Estimates From A Seven Year Follow-Up Of A Nationally Representative Sample Of Older Americans. *Alzheimer's Disease and Dementia*.
3. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The Health Effects of Restricting Prescription Medication Use Due to Cost. *Medical Care*.
4. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Sub-optimal Compliance in Primary and Secondary Prevention Populations: Should We Target Patients With the Most to Gain? *Journal of General Internal Medicine*.
5. Song K, Fendrick AM, Ladabaum U. Fecal DNA Testing Compared To Conventional Cancer Screening Methods: A Decision Analysis. *Gastroenterology*.
6. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick AM. Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the US. *Alimentary Pharmacology & Therapeutics*.

*Articles Submitted for Publication*

1. Campbell BT, Pranikoff T, Fendrick AM, Hirschl RB. Pyloromyotomy: Which Hospitals Did It Better? Submitted to *Pediatrics*.

2. Fendrick AM, Shehab T. New Developments in the treatment of hepatitis C and the role of primary care physicians. Submitted to Archives of Internal Medicine.
3. Fendrick AM, Norris S, Ruffalo SG, Seligman M, Wikler MA. Safety and Efficacy of OTC Cough and Cold Remedies. Submitted to Annals of Internal Medicine.
4. McMahon LF, Hayward RA, Saint S, Chernew M, Fendrick AM. Univariate Solutions in a Multivariate World: Can We Afford to Practice Like the "Good Old Days"? Submitted to New England Journal of Medicine.
5. Cremieux PY, Fastenau J, Kosicki G, Piech CT, Fendrick AM. Once-Weekly Epoetin Alfa for Chemotherapy-Related Anemia: Are Costs of Care Different Than Three Times Per Week Dosing? Submitted to Annals of Pharmacology.
6. Brunton S, Carmichael BP, Colgan R, Feeney AS, Fendrick AM, Quintiliani R. Chronic Bronchitis and an Acute Exacerbation of Chronic Bronchitis. Submitted to Journal of Managed Care.
7. Carlos RC, Fendrick AM, Bernstein SJ. Can Breast and Cervical Cancer Screening Visits Be Used To Enhance Colorectal Cancer Screening? Submitted to Archives of Internal Medicine.
8. Chey WD, Inadomi JM, Booher AK, Sharma VK, Fendrick AM, Howden CW. Primary care physicians' perceptions and practices on the management of GERD: Results of a national survey. Submitted to Archives of Internal Medicine.
9. Stecker EC, Fendrick AM, Knight BP, Fields WB, Aaronson KD. Beta-blocker Therapy In Heart Failure Patients With Bradycardia: Prophylactic Pacemaker Use Is Cost-Effective. Submitted to Journal of American College of Cardiology.
10. Carlos RC, Fendrick AM, Ellis JH, Patterson S, Bernstein SJ. Using Screening Mammography Visits to Enhance Colorectal Cancer Screening. Submitted to American Journal of Roentgenology
11. Ladabaum U, Song K, Fendrick AM. Colorectal Neoplasia Screening with Virtual Colonoscopy:When, at What Cost, and With What National Impact? Submitted to Gastroenterology.
12. Inadomi JM, Fendrick AM. PPI Use in the OTC era: Who to Treat with What and For How Long? Submitted to Journal of Clinical Gastroenterology and Hepatology

#### *Proceedings*

1. Fendrick AM, Goodman CS, Schwartz JS. The Program on Outcomes Research in Technology. Journal of Laparoendoscopic Surgery. 1993;3: 263-67.
2. Fendrick AM. The Need for Outcomes Research in Evaluating the Benefit of Health Care Technology, in *Health Care Technology Policy I: The Role of Technology in the Cost of Health Care*, Warren S. Grundfest, Editor, Proc. SPIE 2307, 125-133 (1994).
3. Fendrick AM. Outcomes Research in Evaluating the Benefit of Health Care Technology, in *Health Care Technology Policy II: The Role of Technology in the Cost of Health Care*, Warren S. Grundfest, Editor, Proc. SPIE 2449, 68-73 (1995).
4. Fendrick AM. Managing Peptic Ulcer Disease in the Era of *Helicobacter pylori*, in *Paradigm: A Practical Guide*, Mary Alderman, Editor, ISSN 1091-8396, (1996).
5. Fendrick AM. Economic Considerations in the Treatment of Reflux Disease. The Management of Acid Peptic Diseases. MPE Communications. 1999;1(2):9-10.
6. Barrardi RR, Fendrick AM. Proton Pump Inhibitors: Update on Comparative Pharmacology, Clinical Efficacy, Safety, and Use in Patients with Acid-Related Diseases. American Council on Pharmaceutical Education, Program No: 424-000-01-032-H01.
7. Saltiel E, Chey W, Fendrick AM. Optimizing Treatment Regimens for Patients at Risk for NSAID-Related Adverse Events: Addressing the Confusion Over "Cox"icity, Program No: 424-000-02-005-H01.

#### *Editorials*

1. Fendrick AM. Towards a National Hepatitis B Vaccination Program. Hospital Practice. 1994;29:9-15.
2. Fendrick AM. Thrombolytic Therapy: Just Do It. Journal of General Internal Medicine. 1995;10:353-354.
3. Tierney WM, Fendrick AM. Economic Evaluation of Alternative Adjuvant Chemotherapy Modalities for Colorectal Carcinoma. J Clin Gastroenterol. 1996;23(4):248-250.

4. Jeffries MA, Scheiman JM, Fendrick AM. *Helicobacter pylori* Eradication: Kill the Bug and Save the Pill? *American Journal of Gastroenterology*. 1998;93(7):1183-1184.
5. Gorelick AB, Scheiman JM, Fendrick AM. Identification of Patients with Resectable Pancreatic Cancer: At What Stage Are We? *American Journal of Gastroenterology*. 1998;93(10):1995-1996.
6. Fendrick AM, Scheiman JM. Healing and Prevention of NSAID-Associated Ulcer Disease: Is Seeing Believing? *American Journal of Gastroenterology*. 1998;93(12):2628-2629.
7. Saint S, Fendrick AM. Economic Immunity in the ICU: Continued Support or Pull the Plug? *Intensive Care Medicine*. 1999;25:345-347.
8. Fendrick AM. Benefit-Based Co-pays: An Alternative Approach to Formulary Management. *Seminars in Medical Practice*. 2000;3(1):32.
9. Fendrick AM, Scheiman JM. Decision Analytic Modeling and NSAID Gastropathy: Could we be More Sensitive? *Journal of General Internal Medicine*. 2000; 15(6):430-431.
10. Scheiman JM, Fendrick AM. NSAID's Without a Prescription: Over-counter Access, Under-counted Risks. *American Journal of Gastroenterology*. 2002; 97(9):2159-2161.
11. Fendrick AM. Mechanisms to Improve Pharmaceutical Use in Managed Care: To Study Controls, Control the Studies [Please]. *American Journal of Managed Care*. 2003;9(11):711-712.
12. Carlos RC, Fendrick AM. Improving Cancer Screening Adherence: Using the "Teachable Moment" as a Delivery Setting for Educational Interventions. *American Journal of Managed Care*. 2004;10(4):247-248.

#### *Chapters in Books*

1. Hillman AL, Fendrick AM. The Technological Imperative. In: Nash DB, ed. Future Practice Alternatives in Medicine. Second Edition. New York: Igaku-Shoin, 1993.
2. Fendrick AM, Schwartz JS. Physicians' Decisions Regarding the Acquisition of Technology. In: Gelijns AC and Dawkins HV, eds. Medical Innovations at the Crossroads. Vol. 4, Adopting New Medical Technology. Washington D.C.: National Academy Press, 1994, pp. 71-84.
3. Fendrick AM. Assessing New Treatments - Biliary Stone Disease. In: Szczepura A and Kankaanpää J, eds. Assessment of Health Care Technologies: Case Studies, Key Concepts and Strategic Issues. New York: John Wiley, 1996, pp.105-122.
4. Chey WD, Fendrick AM. Noninvasive *Helicobacter pylori* Diagnostic Tests-Recent Innovations. Harrison's OnLine World Wide Web. McGraw-Hill. DOI 10.1036/1096-7133.ch284. 4/01/99.
5. Fendrick AM. Clinical and Economic Effects of Nonprescription Therapy in the Treatment of Dyspepsia. In: Johnson DA, Katz PO, and Castell DO, eds. Dyspepsia. American College of Physicians, Philadelphia, PA, 2001, pp.119-134.
6. Inadomi JM, Fendrick AM. Dyspepsia. Physicians Information and Education Resource. <http://pier.acponline.org/physicians/diseases/d169> [Date accessed: 2003 Jan 18] In: PIER [online database]. Philadelphia, American College of Physicians-American Society of Internal Medicine, 2003.
7. Fendrick AM. A Patient at Risk of a Serious Gastrointestinal Events Related to Anti-Inflammatory Therapy. Case-Based Medicine Teaching Series: Acid Related Disorders. McMahon Publishing Group, New York, NY, 2004, pp.86-94.

#### *Book Reviews*

1. Fendrick AM. Review of Orphan Drugs. By Carolyn H. Asbury. *Journal of Policy Analysis and Management*. 1985;5:173.
2. Fendrick AM. Review of Evaluation and Decision Making for Health Services. By James E. Veney and Arnold D. Kaluzny. *Journal of General Internal Medicine*. 1993;2:114.
3. Fendrick AM. Review of Managing the Medical Arms Race. By Susan Bartlett Foote. *Journal of General Internal Medicine*. 1994;9:716.

#### *Letters*

1. Edelson JT, Bohrer MS, Fendrick AM, et al. Premenstrual Syndrome (letter). *New England Journal of Medicine*. 1985; 312:920.
2. Gonzales JJ, Edelson JT, Bohrer MS, Fendrick AM, Morrison MF. Proteinuria and Oral Gold Treatment (letter). *Annals of Internal Medicine*. 1985; 102:561.
3. Fendrick AM. Cost-Effectiveness of Symptomatic Gallstone Management: What Exactly are We Measuring? (letter). *Gastroenterology*. 1992; 102:745-6.
4. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. Cost and Effectiveness of Hepatitis B Vaccination. (letter). *Annals of Internal Medicine*. 1993; 119:536-7.
5. Tierney WM, Fendrick AM. Cost-Effectiveness Model of Colorectal Cancer Screening (letter). *Gastroenterology*. 1996;110:2026-2027.
6. Nallamotheu BK, Saint S, Rubenfire M, Fendrick AM. Electron beam computed tomography in the diagnosis of obstructive coronary artery disease. (letter). *Journal of the American College of Cardiology* 2001; 37:2:689-690.
7. Nallamotheu BK, Saint S, Rubenfire M, Fendrick AM. Electron-beam computed tomography as a population screening tool. (letter). *Archives of Internal Medicine*, 2001;161:2624-2625.
8. Fendrick AM, Smith DG, Chernew ME, Shaw SN. A benefit based copay for prescription drugs: Patient contribution based on total benefits, not drug acquisition cost (letter). *American Journal of Managed Care*, 2002; 8:2:128-130.
9. Cram P, Nallamotheu BK, Fendrick AM, Saint SK. (research letter) Fast Food Franchises in Hospitals. *JAMA*, 2002. 287:22: 2945-2946.
10. Blitz, SG, Chapman, DK, Fendrick, AM. The Role of Physical Therapy in Occupational Low Back Injuries. (letter) *Journal of Occupational and Environmental Medicine*, 2002. 44:6: 489-490.
11. Fendrick AM. Health Investment Costs and Benefits. (letter) *Health Affairs*, 2002. 21(5):300-301.
12. Cram P, Fendrick AM, Vijan S. Public Use of Automated External Defibrillators. (letter) *N Engl J Med*. 2003 Feb 20;348(8):755-6.